$MD
Pediatrix Medical Group, Inc. Stock $md

$md Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000119312515039201 Filed on February 09, 2015

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q2
Revenue	$567.4M	$554.7M	$529.2M
YoY Change	20.39%	17.25%	17.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$409.0M	$401.5M	$386.5M
YoY Change	19.98%	18.02%	19.22%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$10.49M	$10.46M	$9.870M
YoY Change	29.66%	32.0%	28.4%
% of Gross Profit
Operating Expenses	$443.5M	$431.4M	$415.8M
YoY Change	20.41%	17.96%	18.87%
Operating Profit	$123.9M	$123.3M	$113.4M
YoY Change	20.28%	14.82%	13.67%
Interest Expense	$1.046M	$1.507M	$1.673M
YoY Change	-14.19%	141.51%	97.29%
% of Operating Profit	0.84%	1.22%	1.48%
Other Income/Expense, Net		-$1.135M	-$1.277M
YoY Change
Pretax Income	$123.4M	$122.2M	$112.1M
YoY Change	20.4%	13.98%	12.94%
Income Tax	$44.42M	$45.20M	$42.88M
% Of Pretax Income	36.0%	37.0%	38.25%
Net Earnings	$78.97M	$76.96M	$69.22M
YoY Change	19.47%	16.76%	14.33%
Net Earnings / Revenue	13.92%	13.87%	13.08%
Basic Earnings Per Share	$0.79	$0.77	$0.70
Diluted Earnings Per Share	$0.78	$0.76	$0.68
COMMON SHARES
Basic Shares Outstanding	99.47M shares	99.51M shares	99.12M shares
Diluted Shares Outstanding	101.1M shares	101.2M shares	101.1M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.60M	$21.20M	$20.20M
YoY Change	34.77%	-70.51%	30.32%
Cash & Equivalents	$31.14M	$16.24M	$13.16M
Short-Term Investments	$6.500M	$4.900M	$7.000M
Other Short-Term Assets	$8.007M	$9.415M	$9.776M
YoY Change	-13.23%	36.49%	43.74%
Inventory
Prepaid Expenses	$6.361M	$6.076M	$7.055M
Receivables	$285.4M	$272.8M	$269.8M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$368.1M	$373.0M	$367.7M
YoY Change	2.53%	-7.41%	8.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.91M	$60.93M	$61.41M
YoY Change	0.29%	2.91%	2.56%
Goodwill	$2.394B	$2.354B	$2.273B
YoY Change	10.53%	21.36%	25.76%
Intangibles
YoY Change
Long-Term Investments	$57.50M	$61.80M	$59.90M
YoY Change	20.8%	52.59%	22.0%
Other Assets	$129.4M	$130.0M	$127.2M
YoY Change	9.42%	43.34%	41.1%
Total Long-Term Assets	$2.641B	$2.607B	$2.522B
YoY Change	10.43%	22.38%	25.66%
TOTAL ASSETS
Total Short-Term Assets	$368.1M	$373.0M	$367.7M
Total Long-Term Assets	$2.641B	$2.607B	$2.522B
Total Assets	$3.009B	$2.980B	$2.889B
YoY Change	9.39%	17.64%	23.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.61M	$11.47M	$11.74M
YoY Change	34.7%	15.09%	-3.01%
Accrued Expenses	$290.1M	$245.1M	$192.4M
YoY Change	19.98%	14.05%	14.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$326.8M	$274.0M	$212.8M
YoY Change	21.78%	11.89%	7.89%
LONG-TERM LIABILITIES
Long-Term Debt	$27.00M	$123.7M	$154.0M
YoY Change	-81.28%	156.11%	51233.33%
Other Long-Term Liabilities	$60.99M	$63.32M	$57.34M
YoY Change	7.08%	13.35%	-1.91%
Total Long-Term Liabilities	$87.99M	$63.32M	$57.34M
YoY Change	54.49%	13.35%	-1.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$326.8M	$274.0M	$212.8M
Total Long-Term Liabilities	$87.99M	$63.32M	$57.34M
Total Liabilities	$665.7M	$745.8M	$696.2M
YoY Change	-6.89%	27.73%	46.01%
SHAREHOLDERS EQUITY
Retained Earnings	$1.484B	$1.405B	$1.371B
YoY Change	19.03%	19.0%	23.02%
Common Stock	$1.012M	$502.0K	$506.0K
YoY Change	1.2%	0.8%	1.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.343B	$2.234B	$2.193B
YoY Change
Total Liabilities & Shareholders Equity	$3.009B	$2.980B	$2.889B
YoY Change	9.39%	17.64%	23.11%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	$78.97M	$76.96M	$69.22M
YoY Change	19.47%	16.76%	14.33%
Depreciation, Depletion And Amortization	$10.49M	$10.46M	$9.870M
YoY Change	29.66%	32.0%	28.4%
Cash From Operating Activities	$139.3M	$157.9M	$126.6M
YoY Change	32.41%	17.22%	8.11%
INVESTING ACTIVITIES
Capital Expenditures	-$3.000M	-$3.400M	-$5.000M
YoY Change	-34.78%	9.68%	28.21%
Acquisitions
YoY Change
Other Investing Activities	-$41.70M	-$76.50M	-$118.3M
YoY Change	-83.09%	-41.74%	183.69%
Cash From Investing Activities	-$44.70M	-$79.80M	-$123.4M
YoY Change	-82.2%	-40.62%	170.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-79.70M	-75.00M	-24.60M
YoY Change	-178.83%	-239.66%	-69.93%
NET CHANGE
Cash From Operating Activities	139.3M	157.9M	126.6M
Cash From Investing Activities	-44.70M	-79.80M	-123.4M
Cash From Financing Activities	-79.70M	-75.00M	-24.60M
Net Change In Cash	14.90M	3.100M	-21.40M
YoY Change	-133.26%	-94.26%	107.77%
FREE CASH FLOW
Cash From Operating Activities	$139.3M	$157.9M	$126.6M
Capital Expenditures	-$3.000M	-$3.400M	-$5.000M
Free Cash Flow	$142.3M	$161.3M	$131.6M
YoY Change	29.6%	17.05%	8.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	600000000
CY2014Q2	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.75	pure
CY2014Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.375	pure
CY2014Q2	md	Number Of Joint Ventures NumberOfJointVentures	2	JointVenture
CY2014Q2	dei	Entity Public Float EntityPublicFloat	5710786536
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1731016000
CY2011Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	122847000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16165000
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	576030
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18596000
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2035368000
CY2012Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	137036000
CY2012Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	300000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13072000
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	624896
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21280000
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	14900000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101207000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101207000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	37.78
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.74
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1519976	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1966170	shares
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2342988000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	86999000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	326792000
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	235000
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	143000
CY2013Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	43000000
CY2013Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	17946000
CY2013Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	158691000
CY2013Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	27000000
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	143000
CY2013Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	8400000
CY2013Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	-600000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	1012000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18605000
CY2013Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	110300000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1484023000
CY2013Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	19324000
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	111441000
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	13400000
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	189439000
CY2013Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	308754000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2342988000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	60985000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	18150000
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	27000000
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	92000
CY2013Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	23300000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3008716000
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	70800000
CY2013Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	200217000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	857953000
CY2013Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	37818000
CY2013Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	8100000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14902000
CY2013Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	139367000
CY2013Q4	us-gaap	Liabilities Liabilities	665728000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	43403000
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	92000
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	712285
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	27000000
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	80675000
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	712285000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31137000
CY2013Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	17100000
CY2013Q4	us-gaap	Goodwill Goodwill	2393731000
CY2013Q4	us-gaap	Land Land	6683000
CY2013Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5300000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59911000
CY2013Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	57511000
CY2013Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	22981000
CY2013Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	29600000
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	446000
CY2013Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6457000
CY2013Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	41655000
CY2013Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	997682000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16457000
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	146910000
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6385000
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1310000
CY2013Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	117246000
CY2013Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	25799000
CY2013Q4	us-gaap	Assets Assets	3008716000
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	119542000
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	30766000
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	16900000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	285397000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	42425000
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8007000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	129438000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	368125000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	52519000
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	174400000
CY2013Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	103639000
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6361000
CY2013Q4	md	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	162399000
CY2013Q4	md	Accrued Contingent Consideration Liability AccruedContingentConsiderationLiability	19833000
CY2013Q4	md	Accrued Professional Liability AccruedProfessionalLiability	48400000
CY2013Q4	md	Held To Maturity Securities Debt Maturities After Five Through Seven Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughSevenYearsNetCarryingAmount	15856000
CY2014Q4	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Including Subsequent Acquisition Percentage BusinessCombinationStepAcquisitionEquityInterestInAcquireeIncludingSubsequentAcquisitionPercentage	0.75	pure
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96030000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96030000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	46.80
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.57
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	814094	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	27.57
CY2014Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	7100000	shares
CY2014Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.375	pure
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1271044	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	6300000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	814094	shares
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2265566000
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	332000
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	414000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	96895000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	10928000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	416273000
CY2014Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	1320000
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	855000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow	0
CY2014Q4	us-gaap	Business Combination Liabilities Arising From Contingencies Amount Recognized BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized	35300000
CY2014Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	25150000
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	16100000
CY2014Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	168369000
CY2014Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	368000000
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	190855000
CY2014Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	8700000
CY2014Q4	us-gaap	Income Tax Examination Increase Decrease In Liability From Prior Year IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear	300000
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	192000
CY2014Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	700000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	960000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	42000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	10300000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	32783000
CY2014Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	120600000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1376782000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	12347000
CY2014Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	19718000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	130000000
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	10000000
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	160487000
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	465000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	9200000
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	231390000
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	380658000
CY2014Q4	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	488400000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2264619000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58963000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29899000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	96620000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7600000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	16894000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	30000000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	558000000
CY2014Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	10465000
CY2014Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	25900000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3608795000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	100900000
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	253684000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	886877000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	10000000
CY2014Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	38524000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17165000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	21579000
CY2014Q4	us-gaap	Minority Interest MinorityInterest	947000
CY2014Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	148651000
CY2014Q4	us-gaap	Liabilities Liabilities	1343229000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	49858000
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	465000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	8500000
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	848767
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	27272000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10000000
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	568000000
CY2014Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	931800000
CY2014Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	114526000
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	67000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	848767000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47928000
CY2014Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	16000000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20190000
CY2014Q4	us-gaap	Goodwill Goodwill	2776188000
CY2014Q4	us-gaap	Land Land	6683000
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5100000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	66048000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31400000
CY2014Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	64082000
CY2014Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	22981000
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1461000
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	26100000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69100000
CY2014Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	6035000
CY2014Q4	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	54959000
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1200958000
CY2014Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	133279000
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	31400000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10933000
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1524000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14354000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16059000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	162943000
CY2014Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	37289000
CY2014Q4	us-gaap	Assets Assets	3608795000
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	139158000
CY2014Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	45961000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	30985000
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	29000000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	352191000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	48178000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	36874000
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7901000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	235425000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	467052000
CY2014Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	229300000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	62708000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	24919000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	299000000
CY2014Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	198136000
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7036000
CY2014Q4	md	Deferred Tax Liabilities Amortization DeferredTaxLiabilitiesAmortization	214968000
CY2014Q4	md	Line Of Credit Facility Reduction In Available Balance LineOfCreditFacilityReductionInAvailableBalance	200000
CY2014Q4	md	Joint Venture Investment JointVentureInvestment	9500000
CY2014Q4	md	Line Of Credit Facility Potential Increase In Borrowing Capacity LineOfCreditFacilityPotentialIncreaseInBorrowingCapacity	1800000000
CY2014Q4	md	Accrued Contingent Consideration Liability AccruedContingentConsiderationLiability	17010000
CY2014Q4	md	Accrued Professional Liability AccruedProfessionalLiability	47800000
CY2014Q4	md	Number Acquisitions Completed NumberAcquisitionsCompleted	13	Acquisition
CY2014Q4	md	Held To Maturity Securities Debt Maturities After Five Through Seven Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughSevenYearsNetCarryingAmount	9123000
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96083342	shares
CY2013Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	2	pure
CY2014Q4	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2019-10-29
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.78
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3744	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0027	pure
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1857000	shares
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	405398000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	46.48
CY2013	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	2.98
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0263	pure
CY2013	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	19797000
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0048	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0002	pure
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100969000	shares
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.83
CY2013	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	228100000
CY2013	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	100969000	shares
CY2013	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.04
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35000	shares
CY2013	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	99112000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99112000	shares
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	338000
CY2013	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	15654000
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	126411000
CY2013	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2154012000
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28697000
CY2013	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	99000
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	20802000
CY2013	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4695232
CY2013	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1028500000
CY2013	us-gaap	Profit Loss ProfitLoss	280517000
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-212000
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3541000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	448412000
CY2013	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	238045000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	452131000
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3719000
CY2013	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	301076000
CY2013	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	250100000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2955000
CY2013	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	236700000
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	51863000
CY2013	us-gaap	Interest Paid Net InterestPaidNet	3312000
CY2013	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-4607843
CY2013	us-gaap	Net Income Loss NetIncomeLoss	280517000
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	1696000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37331000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31288000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	18981000
CY2013	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2494968000
CY2013	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	19000000
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31300000
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15920000
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	39966000
CY2013	us-gaap	Interest Expense InterestExpense	5415000
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	10739000
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	11480000
CY2013	us-gaap	Operating Expenses OperatingExpenses	1701881000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	33300000
CY2013	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3656000
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1136000
CY2013	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	18579000
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	149722000
CY2013	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5772000
CY2013	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1361318000
CY2013	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	51863000
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24500000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9857000
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167895000
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	134938000
CY2013	us-gaap	Depreciation Depreciation	15500000
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	741000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-132051000
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28697000
CY2013	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	18900000
CY2013	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	18173000
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	17037000
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	29800000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-263490000
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	26400000
CY2013	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	11011000
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	218209000
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	49239000
CY2013	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	911500000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	31288000
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	35400000
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	14784000
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1211000
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	38000
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1425000
CY2013	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	41235000
CY2013	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-8100000
CY2013	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	146760000
CY2013	md	Increase In Uncertain Tax Position IncreaseInUncertainTaxPosition	1800000
CY2013	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	82388000
CY2013	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	33135000
CY2013	md	Number Of Physician Group Practices NumberOfPhysicianGroupPractices	11	Company
CY2013	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	4695232000
CY2013	md	Health Organization Revenue Gross HealthOrganizationRevenueGross	6702484000
CY2013	md	Payment Of Contingent Consideration Liability Operating PaymentOfContingentConsiderationLiabilityOperating	1308000
CY2013	md	Payment Of Contingent Consideration Liability Financing PaymentOfContingentConsiderationLiabilityFinancing	10365000
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.18
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	33569	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	26.16
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Registrant Name EntityRegistrantName	MEDNAX, INC.
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2014	dei	Trading Symbol TradingSymbol	MD
CY2014	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3763	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0033	pure
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1299000	shares
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.    General:</b></font></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The principal business activity of MEDNAX, Inc. (“MEDNAX” or the “Company”) and its subsidiaries is to provide neonatal, anesthesia, maternal-fetal and other pediatric subspecialties physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (“affiliated professional contractors”), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include (i) fee-for-service contracts, whereby hospitals agree, in exchange for the Company’s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company’s affiliated healthcare professionals, and (ii) administrative fee contracts, whereby the Company is assured a minimum revenue level.</font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition to the Company’s national physician network, during 2014 the Company acquired two complementary businesses that offer services to medical providers, including its own, consisting of a revenue cycle management company and a consulting services company. The Company expects that the development of these service offerings will function as support for its own physician practices as well as an outsourced services capability.</font></p> </div>
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	422641000
CY2014	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	Business
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	57.73
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	744794	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500	shares
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	3.27
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0274	pure
CY2014	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	9284000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	529431	shares
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 18px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Accounting Estimates and Assumptions</b></font></p> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are involved in the calculation of the Company’s allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company’s professional liability risks, the fair value of goodwill, and liabilities for uncertain tax positions. Actual results could differ from those estimates.</font></p> </div>
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0059	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0015	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	37.90
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	27.72
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	42.19
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99887000	shares
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.22
CY2014	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y8M12D
CY2014	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	382500000
CY2014	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	99887000	shares
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M6D
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0000893949
CY2014	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.31
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2014	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	At the Company’s option, borrowings under the Credit Agreement (other than swingline loans) will bear interest at (i) the Alternate Base Rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on the Company’s consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on the Company’s consolidated leverage ratio. Swingline loans will bear interest at the alternate base rate plus the applicable margin.
CY2014	us-gaap	Business Combination Separately Recognized Transactions Net Gains And Losses BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses	0
CY2014	us-gaap	Profit Loss ProfitLoss	317203000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1506000
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2137000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	508616000
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4383000
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	326216000
CY2014	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	488600000
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1000	shares
CY2014	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	479394000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	512999000
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1151576	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	98588000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98588000	shares
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	40000
CY2014	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	18061000
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	161841000
CY2014	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2438913000
CY2014	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1	7700000
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	42876000
CY2014	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	159000
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	26884000
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	5403437
CY2014	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1213500000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3750000
CY2014	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	1100000
CY2014	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	479400000
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	488429000
CY2014	us-gaap	Payments For Previous Acquisition PaymentsForPreviousAcquisition	15800000
CY2014	us-gaap	Interest Paid Net InterestPaidNet	7323000
CY2014	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-5266955
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4281000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	317281000
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	2728000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	57018000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31719000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	17479000
CY2014	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1780000
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1244000
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2590384000
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	17500000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31700000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	2559000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45990000
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	42000000
CY2014	us-gaap	Interest Expense InterestExpense	8891000
CY2014	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	13290000
CY2014	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	13583000
CY2014	us-gaap	Operating Expenses OperatingExpenses	1925914000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	28200000
CY2014	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-417000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	297000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	17462000
CY2014	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	170007000
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6998000
CY2014	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1543395000
CY2014	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	488429000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30100000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16791000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	191413000
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	167745000
CY2014	us-gaap	Depreciation Depreciation	15900000
CY2014	us-gaap	Goodwill Transfers GoodwillTransfers	7200000
CY2014	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	293000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	97754000
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42876000
CY2014	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	30100000
CY2014	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	21406000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21109000
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	34300000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-503604000
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	500000
CY2014	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1025000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	27800000
CY2014	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	20735000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	247527000
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	66039000
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-78000
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1754500000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	31719000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	38800000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2262000
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2492000
CY2014	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1527000
CY2014	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	39386000
CY2014	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-16125000
CY2014	md	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeited	0
CY2014	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	179794000
CY2014	md	Increase In Uncertain Tax Position IncreaseInUncertainTaxPosition	2300000
CY2014	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	89002000
CY2014	md	Contributions From Noncontrolling Interest ContributionsFromNoncontrollingInterest	1025000
CY2014	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	23261000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	58000	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97386000	shares
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	102000
CY2012	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	14495000
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	129636000
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1153000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	388171000
CY2012	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	441006000
CY2014	md	Contingent Consideration Payments Related To Prior Period Acquisitions ContingentConsiderationPaymentsRelatedToPriorPeriodAcquisitions	37500000
CY2014	md	Number Of Physician Group Practices NumberOfPhysicianGroupPractices	11	Company
CY2014	md	Business Acquisition Contingent Consideration At Fair Value Decrease BusinessAcquisitionContingentConsiderationAtFairValueDecrease	1600000
CY2014	md	Assumed Payment Probability Of Contingent Consideration Payment AssumedPaymentProbabilityOfContingentConsiderationPayment	1.00	pure
CY2014	md	Business Combination Contingent Consideration Arrangements Time Period BusinessCombinationContingentConsiderationArrangementsTimePeriod	P5Y
CY2014	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	5403437000
CY2014	md	Stock Issued During Period Value Restricted Stock Contingent Consideration StockIssuedDuringPeriodValueRestrictedStockContingentConsideration	705000
CY2014	md	Health Organization Revenue Gross HealthOrganizationRevenueGross	7662556000
CY2014	md	Payment Of Contingent Consideration Liability Operating PaymentOfContingentConsiderationLiabilityOperating	4071000
CY2014	md	Payment Of Contingent Consideration Liability Financing PaymentOfContingentConsiderationLiabilityFinancing	11740000
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.42
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.3794	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0036	pure
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1996000	shares
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	324906000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.06
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0260	pure
CY2012	us-gaap	Malpractice Loss Contingency Period Increase Decrease MalpracticeLossContingencyPeriodIncreaseDecrease	9941000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0015	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0013	pure
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99382000	shares
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.47
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500	pure
CY2012	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1816612000
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	28810000
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	136000
CY2012	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	33120000
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	3994924
CY2012	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	402500000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	389520000
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1349000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2478000
CY2012	us-gaap	Interest Paid Net InterestPaidNet	2044000
CY2012	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-3946058
CY2012	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2397000
CY2012	us-gaap	Profit Loss ProfitLoss	240907000
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	244000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	240907000
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	1896000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17678000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28437000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	6198000
CY2012	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	6200000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28400000
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	21344000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30816000
CY2012	us-gaap	Interest Expense InterestExpense	3245000
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	12564000
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	13133000
CY2012	us-gaap	Operating Expenses OperatingExpenses	1427092000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	23000000
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	3671000
CY2012	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	995000
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1530000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	6494000
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	131754000
CY2012	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-7343000
CY2012	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1130913000
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15000000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2684000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	147264000
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	111940000
CY2012	us-gaap	Depreciation Depreciation	15800000
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	569000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	138326000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28810000
CY2012	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	20800000
CY2012	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	15510000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13980000
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	24800000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-460548000
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	23900000
CY2012	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	28073000
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	193540000
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	16953000
CY2012	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	517500000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	28437000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	18100000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	19814000
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	411000
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2002000
CY2012	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	35441000
CY2012	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-8119000
CY2012	md	Hospital Contract Administrative Fees HospitalContractAdministrativeFees	119746000
CY2012	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	71823000
CY2012	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	27322000
CY2012	md	Contractual Adjustments And Uncollectibles ContractualAdjustmentsAndUncollectibles	3994924000
CY2012	md	Health Organization Revenue Gross HealthOrganizationRevenueGross	5691790000
CY2012	md	Payment Of Contingent Consideration Liability Operating PaymentOfContingentConsiderationLiabilityOperating	786000
CY2012	md	Payment Of Contingent Consideration Liability Financing PaymentOfContingentConsiderationLiabilityFinancing	9445000
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.55
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100784000	shares
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98618000	shares
CY2013Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	502715000
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	90765000
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	91552000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	55367000
CY2013Q1	us-gaap	Investment Income Net InvestmentIncomeNet	402000
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9144000
CY2013Q1	us-gaap	Interest Expense InterestExpense	1189000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	411163000
CY2013Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	329201000
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35398000
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	53318000
CY2013Q1	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	19500000
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100696000	shares
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99076000	shares
CY2014Q1	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	566338000
CY2014Q1	us-gaap	Profit Loss ProfitLoss	63660000
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	104361000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	104097000
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	264000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	63660000
CY2014Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1635000
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10370000
CY2014Q1	us-gaap	Interest Expense InterestExpense	1371000
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	462241000
CY2014Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	372040000
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	40701000
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	58414000
CY2014Q1	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	21417000
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.68
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101098000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.70
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99116000	shares
CY2013Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	529180000
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	112094000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	113371000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	69218000
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	396000
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9870000
CY2013Q2	us-gaap	Interest Expense InterestExpense	1673000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	415809000
CY2013Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	331922000
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42876000
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54601000
CY2013Q2	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	19416000
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99866000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.80
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98411000	shares
CY2014Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	595544000
CY2014Q2	us-gaap	Profit Loss ProfitLoss	79025000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	127969000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	129672000
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1703000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	79016000
CY2014Q2	us-gaap	Investment Income Net InvestmentIncomeNet	335000
CY2014Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	150000
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10361000
CY2014Q2	us-gaap	Interest Expense InterestExpense	2188000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	465872000
CY2014Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	372216000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48944000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60829000
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9000
CY2014Q2	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	22466000
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.76
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101178000	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99506000	shares
CY2013Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	554730000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	122156000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	123291000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	76958000
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	372000
CY2013Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10461000
CY2013Q3	us-gaap	Interest Expense InterestExpense	1507000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	431439000
CY2013Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	346879000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	45198000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	54654000
CY2013Q3	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	19445000
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.86
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100145000	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99088000	shares
CY2014Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	626506000
CY2014Q3	us-gaap	Profit Loss ProfitLoss	86238000
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	137412000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	138143000
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-731000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	86207000
CY2014Q3	us-gaap	Investment Income Net InvestmentIncomeNet	563000
CY2014Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	725000
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11356000
CY2014Q3	us-gaap	Interest Expense InterestExpense	2019000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	488363000
CY2014Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	394794000
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51174000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60643000
CY2014Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	31000
CY2014Q3	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	21570000
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2013Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101080000	shares
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2013Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99469000	shares
CY2013Q4	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	567387000
CY2013Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	123397000
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	123917000
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	78974000
CY2013Q4	us-gaap	Investment Income Net InvestmentIncomeNet	526000
CY2013Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10491000
CY2013Q4	us-gaap	Interest Expense InterestExpense	1046000
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	443470000
CY2013Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	353316000
CY2013Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44423000
CY2013Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	55636000
CY2013Q4	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	24027000
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.89
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99129000	shares
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.90
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98066000	shares
CY2014Q4	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	650525000
CY2014Q4	us-gaap	Profit Loss ProfitLoss	88280000
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	138874000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	141087000
CY2014Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2213000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	88398000
CY2014Q4	us-gaap	Investment Income Net InvestmentIncomeNet	195000
CY2014Q4	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	905000
CY2014Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13903000
CY2014Q4	us-gaap	Interest Expense InterestExpense	3313000
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	509438000
CY2014Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	404345000
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	50594000
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	67641000
CY2014Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-118000
CY2014Q4	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	23549000

Files In Submission

Name	View Source	Status
0001193125-15-039201-index-headers.html	Edgar Link	pending
0001193125-15-039201-index.html	Edgar Link	pending
0001193125-15-039201.txt	Edgar Link	pending
0001193125-15-039201-xbrl.zip	Edgar Link	pending
d846805d10k.htm	Edgar Link	pending
d846805dex1030.htm	Edgar Link	pending
d846805dex211.htm	Edgar Link	pending
d846805dex231.htm	Edgar Link	pending
d846805dex311.htm	Edgar Link	pending
d846805dex312.htm	Edgar Link	pending
d846805dex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g846805ex1030_p01.jpg	Edgar Link	pending
g846805ex1030_p21.jpg	Edgar Link	pending
g846805ex1030_p22.jpg	Edgar Link	pending
g846805ex1030_p24.jpg	Edgar Link	pending
g846805g98d81.jpg	Edgar Link	pending
md-20141231.xml	Edgar Link	completed
md-20141231.xsd	Edgar Link	pending
md-20141231_cal.xml	Edgar Link	unprocessable
md-20141231_def.xml	Edgar Link	unprocessable
md-20141231_lab.xml	Edgar Link	unprocessable
md-20141231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MD
Pediatrix Medical Group, Inc. Stock $md

2013 Q4 Form 10-K Financial Statement

#000119312515039201 Filed on February 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD Pediatrix Medical Group, Inc. Stock $md

2013 Q4 Form 10-K Financial Statement

#000119312515039201 Filed on February 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD
Pediatrix Medical Group, Inc. Stock $md